SCHEMBL5332392

SCHEMBL5332392

O=C(O)c1ccc(NS(=O)(=O)c2ccccn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
MMP2 P08253 2/20 0.51
KMT2A Q03164 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
GRM4 Q14833 1/20 0.50
METAP2 P50579 1/20 0.50
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.48
GAA P10253 2/20 0.47
FABP4 P15090 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PTK2B Q14289 1/20 0.47
GLO1 Q04760 1/20 0.47
SLC40A1 Q9NP59 1/20 0.47
PFKFB3 Q16875 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29184117 0.88 METAP2 (0.47) TSHRMMP2KMT2ACA12CA1
SCHEMBL8164647 0.85 GLO1 (0.55) MMP2KMT2ACA12CA1CA2
SCHEMBL8515156 0.84 PFKFB3 (0.65) MMP2KMT2AMEN1POLBMAPT
SCHEMBL11431819 0.80 KEAP1 (0.57) TSHRKMT2ACA1CA2CA9
SCHEMBL5012450 0.80 ALDH1A1 (0.60) KMT2ACA12CA1CA2CA9
SCHEMBL29184120 0.80 KDM4E (0.58) KMT2AGRM4MEN1MAPTALDH1A1
SCHEMBL4818809 0.79 HDAC3 (0.67)
SCHEMBL15359857 0.78 KAT6A (0.49) MMP2METAP2FABP4GLO1SLC40A1
SCHEMBL893905 0.77 CA12 (0.73) TSHRKMT2ACA12CA1CA2
SCHEMBL31108993 0.76 KDM4E (0.63) TSHRKMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510551-A Pyridine sulfonamide iridium complex, preparation method and high-selectivity catalytic regeneration of NADH (NADH) 烟台大学 2024-02-06 CN disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 US disclosed
US-9156834-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2015-10-13 US disclosed
US-9156834-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2015-10-13 US disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-8846930-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2014-09-30 US disclosed
US-8846930-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2014-09-30 US disclosed
CN-103209980-A Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PF MEDICAMENT 2013-07-17 CN disclosed
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
WO-2012069503-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PIERRE FABRE MEDICAMENT (FR) 2012-05-31 WO disclosed
WO-2007144379-A1 BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS MEDIVIR AB (SE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 TSHR 3945/4885MMP2 707/4885KMT2A 3702/4885
US-20130172326-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY KCNA4, KCNA1, KCNB1 TSHR 560/4885MMP2 4479/4885KMT2A 1058/4885
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY KCNA4, KCNA1, KCNB1 TSHR 560/4885MMP2 4479/4885KMT2A 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.